

iOmx Therapeutics Appoints Rüdiger Wolff as Chief Financial Officer

Martinsried / Munich, Germany, October 1, 2026 – iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing next-generation immuno-oncology therapeutics designed to overcome resistance in solid tumors, today announced the appointment of Rüdiger Wolff as Chief Financial Officer (CFO), effective today.

Rüdiger Wolff joins iOmx with extensive experience in finance leadership roles within the life sciences and technology sectors. He most recently served as Senior Vice President Finance at CureVac, where he contributed significantly to the company's successful Nasdaq IPO in 2020 and held key responsibilities across financing activities, SEC financial reporting and organizational transformation processes. Previously, he held several finance leadership positions at CureVac and Woodward GmbH, with responsibilities across corporate finance, financial operations and international business activities.

"Rüdiger's extensive experience in life sciences finance, capital markets and financial operations will be an important addition to our leadership team," said Dr. Apollon Papadimitriou, Chief Executive Officer of iOmx. "His expertise will help strengthen iOmx's financial and operational capabilities as well as our financial strategy as we continue to advance our diversified pipeline of innovative multi-functional cancer biologics and T cell engagers."

"I am pleased to join iOmx at this important stage of the company's development," said Rüdiger Wolff, Chief Financial Officer of iOmx. "The company is advancing a new generation of targeted immunotherapy treatments designed to address resistance mechanisms in hard-to-treat solid tumors. I look forward to contributing my experience in finance, fundraising and capital markets to support iOmx as it continues to advance its pipeline, strengthen relationships with its high-quality investor base, engage with new investors, and build a strong foundation for future growth."

Rüdiger Wolff is a Certified German Tax Advisor and holds a degree in law from the University of Freiburg. He started his professional career at KPMG and subsequently held finance leadership positions at Praxair, Woodward and CureVac.

About iOmx Therapeutics

iOmx Therapeutics is a biotechnology company developing next-generation immuno-oncology therapeutics designed to overcome resistance in solid tumors. iOmx combines tumor immunology expertise with strong biologics development capabilities to advance a pipeline of multimodal therapeutics, including multi-functional antibodies and T cell engagers.

The company is backed by leading international life science investors, including Athos, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures and Arvantis Social Foundation Impact Investment. iOmx is headquartered in Martinsried/Munich, Germany. For more information, please visit www.iomx.com and follow the company on [LinkedIn](#).



Rüdiger Wolff, Chief Financial Officer of iOmx Therapeutics.

(Photo: iOmx Therapeutics)

High-resolution image material is available at iomx@mc-services.eu.

Media contact

MC Services AG

Katja Arnold, Julia von Hummel, Shaun Brown

T: +49(0)89 2102280

iomx@mc-services.eu